Increased Prevalence of Gastrointestinal Symptoms Associated with Impaired Quality of Life in Renal Transplant Recipients
- 15 February 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Transplantation
- Vol. 83 (3), 282-289
- https://doi.org/10.1097/01.tp.0000251923.14697.f5
Abstract
Background. Immunosuppressive therapies have been associated with gastrointestinal (GI) side effects, which may impair health-related quality of life (HRQoL). Methods. In this survey, 4,232 renal transplant recipients from Denmark, Finland, Norway, and Sweden completed the Short-Form 36 (SF-36) questionnaire and the Gastrointestinal Symptom Rating Scale (GSRS). SF-36 scores were compared with country norm values. Multiple logistic regression analysis was used to identify immunosuppressants associated with GI symptoms. Results. The prevalence of troublesome GI symptoms (GSRS>1) was 83% for indigestion, 69% for abdominal pain, 58% for constipation, 53% for diarrhea, 47% for reflux, and 92% for any GI symptom. Compared with the general population, HRQoL was most commonly meaningfully impaired in the general health dimension (53% of patients). The presence and severity of GI symptoms were associated with worse HRQoL. Tacrolimus showed a significant association with diarrhea (odds ratio [OR]: 1.7; 95% confidence interval [CI]: 1.4–2.0) and constipation (OR: 1.3; 95% CI: 1.1–1.6), and sirolimus with indigestion (OR: 2.9; 95% CI: 1.0–8.1) and abdominal pain (OR: 2.2; 95% CI: 1.1–4.4). Conclusions. GI symptoms are associated with impaired HRQoL in the renal transplant population. Managing GI symptoms by careful choice of immunosuppressants should be a focus for improving HRQoL in renal transplant recipients.Keywords
This publication has 45 references indexed in Scilit:
- Risk factors for dyspepsia in a general population: Non-steroidal anti-inflammatory drugs, cigarette smoking and unemployment are more important thanHelicobacter pyloriinfectionScandinavian Journal of Gastroenterology, 2006
- Impact of mycophenolate mofetil (MMF)‐related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipientsClinical Transplantation, 2005
- Gastrointestinal complications in renal transplant recipientsTransplant International, 2005
- Mycophenolate Sodium Does Not Reduce the Incidence of GI Adverse Events Compared with Mycophenolate MofetilAmerican Journal of Transplantation, 2005
- The Health-Related Quality of Life and Economic Burden of ConstipationPharmacoEconomics, 2005
- Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetilTransplant International, 2004
- Severe gastrointestinal complications after 1,515 adult kidney transplantationsTransplant International, 2004
- Randomized trial of tacrolimus versus cyclosporin microemulsion in renal transplantationPediatric Nephrology, 2002
- Quality of Life in Patients with Upper Gastrointestinal Symptoms: Results from the Domestic/International Gastroenterology Surveillance Study (DIGEST)Scandinavian Journal of Gastroenterology, 1999
- THE EFFECT OF IMMUNOSUPPRESSIVE DRUGS ON QUALITY OF LIFE AFTER RENAL TRANSPLANTATIONTransplantation, 1995